Efficacy of induction cisplatin based chemotherapy in locally advanced non small cell lung cancer
Keywords:
neoadjuvant chemotherapy, locally advanced NSCLCAbstract
Background. Data from the literature demonstrate the efficacy of neoadjuvant or induction chemotherapy in eradicating distant micrometastases, of treating patients with good general conditions and increasing the possibility of a complete resection. It offers potential advantages in the management of non small cell lung cancer. Patients and methods. This study evaluated the efficacy and tolerability of neoadjuvant chemotherapy regimens, with two or three drugs, in locally advanced NSCLC patients (pts) From January 2000 65 pts (58 M + 7 F), mean age 60 years, 29 IIIb and 36 IIIa stage were treated with cisplatin-based chemotherapy: 29 pts in combination with vinorelbine (PV), 21 pts in combination with gemcitabine (PG) and 15 pts in combination with epirubicin and vinorelbine (PEV). Results. The overall response rate was 68%, 40 pts (61%) underwent surgical resection, complete tumour resection was achieved in 34 pts and downstaging was observed in 20 pts. The overall median survival was 22 months, while in resected pts it was 28 months; recurrence of disease was observed in 64% of resected pts. A total of 195 cycles of induction chemotherapy were performed with grade III-IV haematological toxicity: 42% neutropenia and 30% anaemia, while emesis and alopecia were in 26% and 37%, respectively. Conclusion. On the basis of our experience induction doublet chemotherapy combinations PV and PG are feasible, tolerable and effective in pts with locally advanced NSCLC, novel triplet regimens such as PEV should be used in selected groups of pts.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.